Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1754710 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRCYP2C9KDM4EMEN1 | |
| SCHEMBL1261327 | 0.89 | ALDH1A1 (0.55) | ALDH1A1TSHRCYP2C9KDM4EMEN1 | |
| SCHEMBL3021948 | 0.89 | ALDH1A1 (0.55) | ALDH1A1TSHRCYP2C9KDM4EMEN1 | |
| SCHEMBL238242 | 0.87 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP2C9KDM4EMEN1 | |
| SCHEMBL3021950 | 0.87 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP2C9KDM4EMEN1 | |
| SCHEMBL1118954 | 0.87 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP2C9KDM4EMEN1 | |
| SCHEMBL238243 | 0.87 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP2C9KDM4EMEN1 | |
| SCHEMBL13237294 | 0.87 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP2C9KDM4EMEN1 | |
| SCHEMBL238244 | 0.87 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP2C9KDM4EMEN1 | |
| SCHEMBL12722298 | 0.87 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP2C9KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9466827-B2 | Secondary battery | NEC CORPORATION (JP) | 2016-10-11 | — | — | US | claimed |
| US-9466827-B2 | Secondary battery | NEC CORPORATION (JP) | 2016-10-11 | — | — | US | disclosed |
| US-8536205-B2 | Photochromic and electrochromic compounds and synthesis and use thereof | SWITCH MATERIALS INC. (CA) | 2013-09-17 | — | — | US | disclosed |
| US-20130164605-A1 | SECONDARY BATTERY | NEC CORPORATION (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | disclosed |
| US-20100190868-A1 | PHOTOCHROMIC AND ELECTROCHROMIC COMPOUNDS AND SYNTHESIS AND USE THEREOF | SWITCH MATERIALS INC. (CA) | 2010-07-29 | — | — | US | disclosed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | disclosed |
| US-20090088448-A1 | Rapamycin Derivatives and the Uses Thereof in the Treatment of Neurological Disorders | WYETH (US) | 2009-04-02 | — | — | US | disclosed |
| US-7476678-B2 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | WYETH (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1888553-A1 | PHOTOCHROMIC AND ELECTROCHROMIC COMPOUNDS AND SYNTHESIS AND USE THEREOF | Switch Materials Inc. (CA) | 2008-02-20 | — | — | EP | disclosed |
| US-20080027089-A1 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-7273874-B2 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | WYETH (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1828203-A2 | RAPAMYCIN DERIVATIVES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Wyeth (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1807429-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM, LLC (BM) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006125317-A1 | PHOTOCHROMIC AND ELECTROCHROMIC COMPOUNDS AND SYNTHESIS AND USE THEREOF | SWITCH MATERIALS INC. (CA) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006068905-A2 | RAPAMYCIN DERIVATIVES AND THE USES THEREOF IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WYETH (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135550-A1 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | WYETH (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006047516-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135550-A1 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | MTOR, RPTOR, RICTOR | ALDH1A1 3254/4885TSHR 1065/4885CYP2C9 2858/4885 |
| US-20100190868-A1 | PHOTOCHROMIC AND ELECTROCHROMIC COMPOUNDS AND SYNTHESIS AND USE THEREOF | HCN2, HCN1, SCO2 | ALDH1A1 488/4885TSHR 4023/4885CYP2C9 515/4885 |
| US-20090088448-A1 | Rapamycin Derivatives and the Uses Thereof in the Treatment of Neurological Disorders | RICTOR, BDNF, NLN | ALDH1A1 2988/4885TSHR 4225/4885CYP2C9 3675/4885 |
| US-20080027089-A1 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders | RPTOR, MTOR, RICTOR | ALDH1A1 3946/4885TSHR 1903/4885CYP2C9 2874/4885 |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | ALDH1A1 2743/4885TSHR 2250/4885CYP2C9 1295/4885 |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | ALDH1A1 2743/4885TSHR 2250/4885CYP2C9 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.